We will have limited operations from 15:00 Wednesday 24 December 2025 (AEDT) until Friday 2 January 2026. Find out how to contact us during the holiday period.
AJOVY Teva Pharma Australia Pty Ltd
Product name
AJOVY
Sponsor
Accepted date
Oct-2025
Active ingredients
Fremanezumab
Proposed indication
Ajovy (fremanezumab) is proposed as a preventive treatment of episodic migraine (less than 15 migraines per month) in children aged 6 years and older, weighing at least 45 kg.
Application type
C (new indication)
Publication date
Oct-2025